Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.

Sientra, Inc.

MyWebAR is a platform that enables users to create and launch augmented reality experiences without needing a professional developer team. It allows for the design of experiences for marketing, retail, education, and enterprise purposes, as well as interactive product previews.

MyWebAR

Sientra specializes in breast augmentation and breast reconstruction services with a focus on silicone gel breast implants.

Sientra

Sientra, a Tiger Aesthetics Brand | 12,329 followers on LinkedIn. See Unrivaled Safety. See State-of-the-Art Science. See Exceptional Service. | Sientra, a Tiger Aesthetics Medical, LLC brand, offers leading transformative treatments and technologies focused on progressing the art of plastic surgery and making a difference in patients’ lives. With unrivaled safety, state-of-the-art science and exceptional service; paired with unparalleled partnerships with plastic surgeons, the Sientra portfolio of proprietary innovations radically advances how plastic surgeons think, work and care for their patients. The company’s core breast products segment includes its state-of-the-art Sientra breast implants, its portfolio of  tissue expanders, including the revolutionary AlloX2® dual-port breast tissue expander with integrated drain and Viality™, a new standard in fat transfer technology.

Member Board Of Directors

Philippe Schaison

Medical Device/Breast Reconstruction and Aesthetics Business Director of Sales - Southeast

Claire Adams

Christopher M. Brett

David Stock

Sientra, a Tiger Aesthetics Brand

We’re excited to announce the acquisition of Revelle Aesthetics, makers of the Avéli® cellulite reduction device. The Avéli device is the only single-use disposable device that enables visualization and targeted release of the specific septa causing the cellulite dimples. The minimally invasive procedure is performed in-office under local anesthesia and can be administered by both licensed and trained physicians, as well as mid-level providers in many states. With the Revelle acquisition, we can now provide a comprehensive and differentiated suite of combination options for lower body rejuvenation, inclusive of Avéli for cellulite, Viality™ for enhanced viability fat transfer, and the forthcoming alloCLAE™ and dermaCLAE™ structural adipose fillers to augment volume in aesthetic body procedures. We're excited to continue leading the way in regenerative and aesthetic solutions. Learn more about the acquisition here: https://lnkd.in/eTyCQBA9 #TigerAestheticsMedical #Avéli #RevelleAesthetics

Tiger Aesthetics, the parent company of Sientra, has significantly expanded its portfolio with the acquisition of three ground breaking brands from Suneva Medical: Bellafill, Silhouette Instalift and Amplifine PRP. This marks a major step in expanding our offerings and enhancing both facial and full-body aesthetics. With these innovative products, we’re providing our customers with new clinical applications and revenue opportunities to help grow their practices. We're excited to continue leading the way in regenerative and aesthetic solutions. Learn more about the acquisition here: https://lnkd.in/eV2HEPKq #sientra #TigerAestheticsMedical #AestheticInnovation #Bellafill #SilhouetteInstaLift #AmplifinePRP #RegenerativeAesthetics

We're excited to introduce ourselves! We at Tiger Aesthetics are committed to bringing advanced and effective regenerative technologies to aesthetics and reconstruction. Alongside our legacy of expertise in tissue engineering, we've brought together an array of trusted surgical brands, including Sientra, Viality and AlloX2 to drive innovation in the fields of reconstruction and aesthetic medicine. Stay tuned as we build the future of regenerative aesthetics! #tigeraesthetics #newera #sientra #viality #alloClae

Tiger Aesthetics is committed to giving back to the community, starting with our support of Mission Plasticos’ Reshaping Lives: Full Circle initiative. We’re pleased to forge a long-term, stable partnership with Mission Plasticos to impact care for patients in need and provide women access to life-changing breast reconstruction procedures. Want to get involved? Reach out to your local Tiger Aesthetics plastic surgery consultant. Read more: https://lnkd.in/gD3REQKB

Day 2 at #TheAestheticMeeting2024 in beautiful Vancouver,BC! Come hear Dr. Steven Cohen, MD, FACS speak to Viality(TM), a new standard in Fat Transfer in The Aesthetic Arena at 12:23! #Sientra #TigerAesthetics #TheAestheticMeeting2024 #TheAestheticSociety #Viality

The future of regenerative aesthetics is sooner than you think! We’ll see you Thursday through Sunday at The Aesthetics Meeting! Booth #1203 #Sientra #TigerAesthetics #TheAestheticMeeting2024 The Aesthetic Society

The Sientra team is gearing up for a great few days in Dallas! Experience the Sientra difference with a leading portfolio that spans a complete spectrum of plastic and reconstruction solutions when you stop by the Sientra booth this Thursday and Friday! Dallas Rhinoplasty Cosmetic Symposium #Sientra #SeeYourSkillsInSientra #Innovation #BreastAugmentation #BreastReconstruction

We hope to see you this Thursday in Whistler at MWSPS24. Experience the Sientra difference with a leading portfolio that spans a complete spectrum of plastic and reconstruction solutions when you stop by the Sientra booth this Thursday through Sunday! #Sientra #SeeYourSkillsInSientra #Innovation #MWSPS24

Will we see you in New Mexico this week? Join Sientra at the 2024 Women in Plastic Surgery Symposium to recharge, connect and learn of the latest in surgical techniques & innovation. Swing by the Sientra booth to see how you can bring a new standard in fat transfer to your cosmetic & reconstructive practice. Adelle Walker Kristin Cullen

Season's Greetings from Sientra®! Wishing you a wonderful holiday season 🧡 _ #Holidays #SeasonsGreetings #Sientra

Metric
Company Name	Sientra, Inc.	MyWebAR
Symbol	SIEN
MSH ID	COM:SIENTRA	COM:MYWEBAR
Market	STOCKS	PRIVATE
Sector	Healthcare	Technology
Industry	Medical - Devices	Augmented Reality
Country	US	DE
Stage	Post-IPO Equity
Employee Count	304
Website	sientra.com	mywebar.com
LinkedIn	sientra
Founders

Metric
Market Cap	2.08M
Enterprise Value
Monthly Web Traffic	3.29K	809.35K
Web Traffic Growth	-0.11	0.32
Valuation
Raised Capital	13.20M

Metric
Revenue	90.55M
Revenue (LTM)
Revenue (NTM)
Gross Profit	41.59M
EBITDA	-62.27M
Operating Income	-69.05M
Net Income	-73.72M
EPS	-10.27
Diluted EPS	-10.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.42
Operating Profit Margin	-0.57
EBITDA Margin	-0.69
Net Profit Margin	-0.71
Return on Equity	4.15
Return on Assets	-0.46
Return on Capital Employed	4.24

COM:SIENTRA

Sientra

Last Close

0.21

21/02 21:00

Market Cap

2.08M

Beta: -

Volume Today

3.33M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.11
P/B Ratio	-0.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.02
EV Multiple	1.05

Metric
Days Sales Outstanding	119.69
Days Payables Outstanding	36.89
Days Inventory Outstanding	274.17
Operating Cycle	393.86
Cash Conversion Cycle	356.96
Asset Turnover	0.65

Metric
Operating Cash Flow	-35.29M
Free Cash Flow	-38.88M
Cash Flow to Debt	-0.19
Operating Cash Flow/Sales	-0.13
Free Cash Flow Yield	-2.02

Metric
Cash & Equivalents	26.07M
Accounts Receivable	-5.26M
Inventory	42.69M
Goodwill	9.20M
Debt to Capitalization	2.04
Debt to Assets	0.45
Current Ratio	0.57
Quick Ratio	0.29

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.07
R&D to Revenue	0.13
SG&A to Revenue	0.38